|
| Status |
Public on Aug 20, 2019 |
| Title |
Cyclophosphamide (CTX) Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression |
| Organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Purpose: To understand the molecular mechanisms underlying the CTX synergization with antibody therapies in resistant niche-specific organs and BM-resident tumors
|
| |
|
| Overall design |
Humanized mice were treated with CTX or PBS. Two days post treatment, mouse and human macrophages in the spleen and bone were sorted and applied to RNAseq.
|
| |
|
| Contributor(s) |
Roghanian A, Hu G |
| Citation(s) |
31451483 |
| |
| Submission date |
Aug 19, 2019 |
| Last update date |
Jan 11, 2021 |
| Contact name |
Guangan Hu |
| E-mail(s) |
[email protected]
|
| Organization name |
MIT
|
| Department |
Koch Institute
|
| Lab |
Chen
|
| Street address |
500 Main Street
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02139 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
| GPL13112 |
Illumina HiSeq 2000 (Mus musculus) |
|
| Samples (16)
|
|
| Relations |
| BioProject |
PRJNA560906 |
| SRA |
SRP218840 |
Less...
More...